Castalagin
Castalagin is an orally active natural product with multiple biological activities including antibacterial activity against bacteria and anti-leishmanial activity against Leishmania aethiopica. Castalagin exhibits inhibitory activity against PARP1 and DNA topoisomerase II, with an IC50 of 0.86 μM for bovine PARP1. Castalagin reduces poly (ADP-ribosyl) ation modification in cells. Castalagin binds to the cell envelope of Ruminococcus bromii, increases the ratio of CD8+/FOXP3+CD4+ T cells in the tumor microenvironment, and acts as a prebiotic to enhance the activity of anti-PD-1 therapy. Castalagin induces morphological changes in Leishmania aethiopica promastigotes and inhibits their proliferation. Castalagin inhibits PBP2a-mediated peptidoglycan layer stabilization, disrupts bacterial peptidoglycan assembly, and inhibits and disintegrates bacterial biofilms. Castalagin can be used in research related to diseases such as cancer, leishmaniasis, and bacterial infections.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- CAS No.: 24312-00-3
- 화학식: C41H26O26
- 분자량:934.63
-
보관:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
제품 설명
|
PARP1 0.86 μM (IC50) |
Topoisomerase II |
Leishmania |
In Vitro
Castalagin potently inhibits purified bovine thymus PARP1 in a mixed-type manner, with an IC50 of 0.86 μM and a Ki of 1.64 μM; it inhibits the activity of human recombinant DNA topoisomerase II in vitro at concentrations of 0.1 and 0.3 μM[1].
Castalagin (0.1-3.2 μM; 24 h) reduces poly (ADP-ribosyl) ation in human neuroblastoma SH-SY5Y cells[1].
Castalagin exhibits stronger DPPH free radical scavenging activity than the non-enriched cork water extract[4].
Castalagin (0.125-2.00 mg/mL; 24 h) shows cytocompatibility with L929 fibroblasts at its anti-MRSA MIC concentration of 0.125 mg/mL after 24 h of incubation, but exhibits cytotoxicity at higher concentrations[4].
Castalagin labeled with fluorescein (2 μmol/L; 1 h at 37°C) preferentially binds to the cell envelope of Ruminococcus bromii, and the intensity of its specific competitive binding is higher than that to Ruminococcus bicirculans, Bacteroides thetaiotaomicron, or Escherichia coli[2].
Castalagin inhibits and kills MRSE (MIC = 0.250 mg/mL), SA (MIC = 0.500 mg/mL), MRSA (MIC = 0.125 mg/mL) and PA (MIC = 1.000 mg/mL) in the microbroth dilution assay, and exhibits stronger efficacy against methicillin-resistant Gram-positive strains[4].
Castalagin (0.125-1.000 mg/mL; 24 h) significantly reduces the viable cell count, damages the cell wall, and decreases the cell density of MRSE, SA, MRSA, and PA at its corresponding MIC[4].
Castalagin (0.020-1.00 mg/mL; 24 h) disrupts preformed biofilms of MRSE, SA, MRSA and PA, and exerts effective activity against Gram-positive strains at concentrations below its MIC[4].
Castalagin (0.050-0.500 mg/mL; 24 h) inhibits biofilm and β-sheet structure formation of MRSE, SA and MRSA, and disturbs the synthesis of biofilm constituents in PA[4].
Castalagin-loaded alginate hydrogel inhibits the growth of MRSE, MRSA and SA, exerts no growth inhibitory effect on PA, and exhibits cytocompatibility when incubated with L929 fibroblasts[4].
Castalagin potently inhibits the proliferation and kills promastigotes of Leishmania aethiopica and Leishmania amazonensis, with corresponding MIC values of 55 μg/mL (0.059 μM) and 65 μg/mL (0.070 μM)[3].
Castalagin (55 μg/mL; 24 h) induces morphological damage, including swelling and loss of spindle shape, in promastigotes of Leishmania aethiopica, which subsequently leads to their death; it also causes ultrastructural damage in Leishmania aethiopica promastigotes, including cytoplasmic swelling, nuclear changes, and flagellar pocket swelling, thereby resulting in death[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:human neuroblastoma SH-SY5Y cells
-
Concentration:0.1, 0.3, 1.1, 3.2 μM
-
Incubation Time:24 h
-
Result:Attenuated cellular poly(ADP-ribosyl)ation.
Caused a noticeable reduction in PARylated proteins (including automodified PARP1) at 3.2 μM.
-
Cell Line:L929 mouse fibroblast cell line
-
Concentration:0.125, 0.25, 0.5, 1, 2 mg/mL
-
Incubation Time:24 h
-
Result:Was cytocompatible at 0.125 mg/mL (its MRSA MIC concentration), with no significant reduction in metabolic activity relative to untreated controls.
Caused statistically significant reductions in metabolic activity at concentrations ≥ 0.250 mg/mL.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6 (female, seven weeks old, subcutaneous implantation of 0.8 × 106 MCA-205 fibrosarcoma cells)[2]
-
Dosage:0.21 mg/kg; 0.85 mg/kg; 1.28 mg/kg; 2.55 mg/kg
-
Administration:p.o.; daily
-
Result:Equaled CC in tumor shrinkage at 0.85 mg/kg and outperformed water controls.
Generated saturated antitumor activity at doses ≥ 0.85 mg/kg.
Showed no antitumor activity at 0.21 mg/kg.
Raised fecal Ruminococcaceae abundance at 0.85 mg/kg, with no improvement at higher doses.
Chemical Information
-
CAS No. 24312-00-3
-
분자량 934.63
-
화학식 C41H26O26
-
SMILES
O=C(O[C@]1([C@@H]([C@@]([H])(OC(C2=C3C(O)=C(C(O)=C2C4=C(C(O)=C(C(C5=C(C(O)=C(C=C56)O)O)=C47)O)O)O)=O)[C@H]3O)OC7=O)[H])C8=CC(O)=C(C(O)=C8C9=C(C=C(C(O)=C9O)O)C(OC[C@]1(OC6=O)[H])=O)O
-
Structure Classification
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocol
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
-
Multiplex immunofluorescence IHC
Multiplex immunofluorescence IHC detects multiple protein biomarkers in one tissue section by sequential antibody staining, HRP-mediated tyramide fluorophore deposition, heat-mediated antibody stripping, nuclear counterstaining, multispectral imaging, spectral unmixing, and digital cell phenotyping; TSA deposits fluorophore near the antigen so the fluorescence signal remains after primary and secondary antibodies are removed, enabling repeated staining cycles, including with antibodies from the same host species. Classic FFPE tumor immune-profiling applications use panels such as CD3, CD8, CD68/CD163, FOXP3, PD-1, PD-L1, pancytokeratin, Ki67, and DAPI to identify tumor cells, immune-cell subsets, checkpoint-marker expression, co-expression phenotypes, cell density, and spatial relationships in the tumor microenvironment.
-
Multiplex immunohistochemistry
Multiplex immunohistochemistry (mIHC), also known as tyramide dignal amplification (TSA), is an enzymatic detection method that uses horseradish peroxidase (HRP) to perform high-density in-situ labeling of target proteins or nucleic acids.
-
Bacterial live/dead nucleic-acid viability staining
The LIVE/DEAD bacterial viability staining method is based on differential permeability of nucleic-acid-binding fluorescent dyes, most commonly SYTO 9 and propidium iodide (PI), which enables discrimination of bacterial populations with intact versus compromised cytoplasmic membranes. SYTO 9 penetrates both intact and damaged bacterial membranes and binds nucleic acids to produce green fluorescence, whereas propidium iodide penetrates only cells with compromised membranes and fluoresces red while also reducing SYTO 9 signal through competitive binding and fluorescence interactions. The resulting fluorescence pattern is interpreted as a proxy for membrane integrity, which is widely used as an indicator of bacterial viability in microscopy, flow cytometry, and spectroscopic platforms. However, mechanistic studies show that SYTO 9 and PI interactions involve displacement and fluorescence resonance energy transfer effects, which can influence signal interpretation depending on dye ratios a
-
Research Protocol for Cancer Immunology
Cancer immunology studies how the immune system recognizes, suppresses, edits, or fails to eliminate malignant cells through tumor antigen release, antigen presentation, T-cell priming, immune trafficking, tumor-cell killing, and feedback inhibition in the tumor microenvironment. The cancer-immunity cycle links tumor antigenicity, dendritic-cell priming, CD8+ T-cell infiltration, cytotoxic function, and immune-checkpoint regulation to tumor rejection or immune escape. Immune-checkpoint pathways such as PD-1/PD-L1 and CTLA-4 suppress antitumor T-cell activity and can be therapeutically blocked, but many tumors remain resistant because of poor antigen presentation, weak T-cell infiltration, suppressive myeloid cells, regulatory T cells, and tumor-intrinsic immune-exclusion programs. Unresolved questions include which immune-cell states predict response, how tumor-intrinsic pathways exclude immune cells, how myeloid suppression limits checkpoint blockade, and which combination strategies
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
순도&문서
References
[1]. Kamada Y, et al. Castalagin and vescalagin purified from leaves of Syzygium samarangense (Blume) Merrill & L.M. Perry: Dual inhibitory activity against PARP1 and DNA topoisomerase II. Fitoterapia. 2018 Sep;129:94-101. [Content Brief]
[2]. Messaoudene M, et al. A Natural Polyphenol Exerts Antitumor Activity and Circumvents Anti-PD-1 Resistance through Effects on the Gut Microbiota. Cancer discovery. 2022 Apr 01;12(4):1070-1087. [Content Brief]
[4]. Araújo AR, et al. Vescalagin and Castalagin Present Bactericidal Activity toward Methicillin-Resistant Bacteria. ACS biomaterials science & engineering. 2021 Mar 08;7(3):1022-1030. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)